Commentary (Collins/Hurwitz)—Epidermal Growth Factor Receptor Inhibitors for the Treatment of Colorectal Cancer: A Promise Fulfilled?
Damjanov and Meropol have
done an excellent job of reviewing
both the complex biology
of epidermal growth factor signaling
and the current status of
epidermal growth factor receptor
(EGFR, ErbB-1) inhibition for the
treatment of colorectal cancer. As they
point out, several factors have made
EGFR a potentially high-value target
in cancer therapy. In addition, they
review several phase II studies that
have demonstrated clinical activity for
anti-EGFR antibodies in patients with
advanced colorectal cancer.